

\$5,000,000



Follow-On

Sole Placement Agent

JULY 2022

## Roth Capital Partners Acted as Sole Placement Agent for Revelation Biosciences Inc. (Nasdaq:REVB) in its \$5 Million Follow-On

**For more information please contact:**

### Investment Banking

**James Antonopoulos**  
Managing Director &  
Head of Healthcare  
Investment Banking  
(646) 358-1906  
[jantonopoulos@roth.com](mailto:jantonopoulos@roth.com)

**Aparna Beeram**  
Vice President  
(646) 358-1912  
[abeeram@roth.com](mailto:abeeram@roth.com)

### Equity Capital Markets

**Aaron Gurewitz**  
Head of Equity  
Capital Markets  
(949) 720-5703  
[agurewitz@roth.com](mailto:agurewitz@roth.com)

**Nazan Akdeniz**

### Transaction Information

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic-based therapies for the prevention and treatment of disease, announced the closing on July 28, 2022 of its previously announced public offering of 8,333,334 shares of its common stock, together with warrants to purchase up to 8,333,334 shares of its common stock at an offering price to the public of \$0.60 per share and associated warrant. The warrants have an exercise price of \$0.60 per share, are exercisable upon issuance, and will expire five years following the date of issuance.

Roth Capital Partners acted as sole placement agent for the offering.

### About Revelation Biosciences Inc.

Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has multiple product candidates in development. REVTx-99b, the lead therapeutic

Senior Vice President  
(949) 720-5740  
[nakdeniz@roth.com](mailto:nakdeniz@roth.com)

Lou Ellis  
Senior Vice President  
(949) 720-5739  
[lellis@roth.com](mailto:lellis@roth.com)

candidate, is being developed for allergic rhinitis. REVDx-501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation. Revelation has engaged MedWorld Advisors to facilitate partnering of the REVDx-501 asset. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with a traditional intramuscular vaccination for more complete immunity. For further information about the Company, please visit [www.revbiosciences.com](http://www.revbiosciences.com). (Source: Company Website 8.1.22)

#### **About Roth Capital Partners**

Roth Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, Roth provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, Roth is privately-held and employee owned, and maintains offices throughout the U.S. For more information on Roth, please visit [www.roth.com](http://www.roth.com).

---

[About Roth](#) | [Investment Banking](#) | [Capital Markets](#) | [Institutional Sales & Trading Research](#) | [Corporate Services](#) | [Corporate Access & Conferences](#) | [Press Room](#)

---

Date of Announcement: 8.5.22

The material, information and facts discussed in this announcement other than the information regarding Roth Capital Partners, LLC ("Roth") and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This announcement should not be used as a complete analysis of any companies, securities or topics discussed herein. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this announcement are subject to change without notice. An investment in any security based on this announcement may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, such investments may involve a high degree of risk and may not be suitable for all investors. No part of this announcement may be reproduced in any form without the express written permission of Roth. Copyright 2022.



ROTH Capital Partners, LLC

888 San Clemente Drive, Newport Beach CA, 92660 | Member SIPC / FINRA | [www.roth.com](http://www.roth.com)